Capital Fund Management (CFM)’s Alexion Pharmaceuticals ALXN Stock Holding History

Capital Fund Management (CFM)’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-14,300	Closed	-$1.28M	–	1723
2020 Q1	$1.28M	Buy	+14,300	New	+$1.4M	0.02%	683
2019 Q3	–	Sell	-2,300	Closed	-$301K	–	1981
2019 Q2	$301K	Buy	+2,300	New	+$296K	﹤0.01%	1379
2016 Q2	–	Sell	-5,300	Closed	-$738K	–	1876
2016 Q1	$738K	Buy	+5,300	New	+$778K	0.01%	994
2015 Q2	–	Sell	-4,000	Closed	-$693K	–	1769
2015 Q1	$693K	Buy	4,000 +2,100	+111%	+$380K	0.01%	918
2014 Q4	$352K	Sell	1,900 -2,500	-57%	-$463K	﹤0.01%	1279
2014 Q3	$730K	Sell	4,400 -3,600	-45%	-$591K	0.01%	1025
2014 Q2	$1.25M	Buy	+8,000	New	+$1.26M	0.01%	879
2014 Q1	–	Sell	-3,500	Closed	-$466K	–	2029
2013 Q4	$466K	Sell	3,500 -14,200	-80%	-$1.7M	0.01%	1283
2013 Q3	$2.06M	Sell	17,700 -8,500	-32%	-$933K	0.03%	634
2013 Q2	$2.42M	Buy	+26,200	New	+$2.52M	0.04%	569

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Fund Management (CFM)'s ALXN Position: Q3 2020 in Review

Capital Fund Management (CFM) sold out of Alexion Pharmaceuticals (ALXN) in Q3 2020, closing a stake of 49,084 shares — an estimated $5.51M sold.

Capital Fund Management (CFM) first reported a position in ALXN in Q2 2013 and held it in 10 quarters. The position peaked at $58.2M in Q2 2017. 707 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

Capital Fund Management (CFM) reported no remaining Alexion Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Capital Fund Management (CFM) sold 49,084 Alexion Pharmaceuticals shares in Q3 2020, an estimated $5.51M.
Capital Fund Management (CFM) first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 10 quarters.
Capital Fund Management (CFM)'s Alexion Pharmaceuticals position peaked at $58.2M in Q2 2017.
707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2020, filed 13 Nov 2020.